PCN83 Healthcare Resource Utilization (HCRU) of Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer (EC/GEJC) Receiving Adjuvant Nivolumab Treatment Versus Placebo:
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.175
https://www.valueinhealthjournal.com/article/S1098-3015(21)00392-2/fulltext
Title :
PCN83 Healthcare Resource Utilization (HCRU) of Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer (EC/GEJC) Receiving Adjuvant Nivolumab Treatment Versus Placebo:
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00392-2&doi=10.1016/j.jval.2021.04.175
First page :
Section Title :
Open access? :
No
Section Order :
10752